Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 15, 2020
Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC studyShadi Yaghi, Nils Henninger, Erica Scher, et al.Journal of the American Heart Association|July 29, 2021
Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke StudyShadi Yaghi, Eva Mistry, Adam de Havenon, et al.Annals of Neurology|September 11, 2009
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIPetra Kaufmann, John L P Thompson, Gilberto Levy, et al.Stroke|August 8, 2020
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC StudyShadi Yaghi, Eva Mistry, Ava L Liberman, et al.Annals of Neurology|March 19, 2020
Blood Pressure Goals and Clinical Outcomes after Successful Endovascular Therapy: A Multicenter StudyMohammad Anadani, Adam S Arthur, Georgios Tsivgoulis, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|May 17, 2020
Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillationShadi Yaghi, Ava L Liberman, Nils Henninger, et al.JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.Pageof 5